Compare CHCT & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHCT | EMBC |
|---|---|---|
| Founded | 2014 | 1924 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 372.5M | 354.1M |
| IPO Year | 2015 | 2021 |
| Metric | CHCT | EMBC |
|---|---|---|
| Price | $14.66 | $6.39 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 4 |
| Target Price | ★ $17.00 | $4.00 |
| AVG Volume (30 Days) | 345.0K | ★ 778.1K |
| Earning Date | 11-03-2026 | 11-24-2026 |
| Dividend Yield | ★ 8.97% | 0.62% |
| EPS Growth | ★ 134.78 | 20.90 |
| EPS | 0.22 | ★ 1.03 |
| Revenue | ★ $121,195,000.00 | N/A |
| Revenue This Year | $4.65 | N/A |
| Revenue Next Year | $4.57 | $5.59 |
| P/E Ratio | $66.82 | ★ $6.27 |
| Revenue Growth | ★ 4.67 | N/A |
| 52 Week Low | $12.58 | $2.77 |
| 52 Week High | $19.17 | $14.81 |
| Indicator | CHCT | EMBC |
|---|---|---|
| Relative Strength Index (RSI) | 60.58 | 53.44 |
| Support Level | $14.39 | $5.64 |
| Resistance Level | $17.96 | $6.85 |
| Average True Range (ATR) | 0.40 | 0.33 |
| MACD | 0.20 | -0.03 |
| Stochastic Oscillator | 76.40 | 55.61 |
Community Healthcare Trust Inc is an integrated healthcare real estate company in the United States. The company owns and acquires, or finances, real estate properties that are leased to hospitals, doctors, healthcare systems, or other healthcare service providers in non-urban markets. The company derives the majority of its revenues from its real estate property and mortgage notes portfolio. The company's rental and mortgage interest income is recognized based on contractual arrangements with its tenants and borrowers.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.